Indefinite Delivery Contract SPE2DR25D3021

The Indefinite Delivery Contract (IDC) SPE2DR25D3021 is a $9,999,999,999 single-award contract issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp. The contract provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The IDC serves as the primary vehicle for the DLA Troop Support Medical's Pharmaceutical Prime Vendor Global Program Generation V, which aims to establish prime vendor contracts to provide worldwide pharmaceutical support to various DoD customers, including the Defense Health Agency, U.S. Coast Guard, and U.S. Naval Fleet. The contract covers an extensive array of medical commodities, such as specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits, across multiple therapeutic domains. The IDC has a 30-month base period and three 30-month option periods, with an estimated total value of $30.3 billion for the program. This unrestricted, fully competitive acquisition will be awarded based on the lowest overall price, with the intention to make multiple regional awards to at least three different contractors to ensure supply chain resiliency.

In addition to the DLA IDC, Amerisourcebergen also holds a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation through May 2024, which covers similar medical products and prescription drugs. These comprehensive IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries through a streamlined contracting mechanism.